Title

Non-intravenous, carbapenem-sparing antibiotics for the treatment of bacteremia due to ESBL or Amp-C β -lactamase: A propensity score study.

Authors

Y. Meije¹, C. Pigrau^{2,3}, N. Fernández-Hidalgo^{2,3}, M. Clemente¹, L. Ortega¹, X. Sanz¹, J. Loureiro-Amigo¹, M. Sierra⁴, A. Ayestaran⁵, A. Morales-Cartagena¹, A. Ribera¹, J. Rodríguez-Baño^{3,6}, J. Martínez-Montauti¹

¹Infectious Diseases Unit – Internal Medicine Department. Hospital de Barcelona. Societat Cooperativa d'Instal·lacions Assistencials Sanitàries (SCIAS). Barcelona, Spain.

²Servei de Malalties Infeccioses. Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.

³Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain.

⁴Microbiology Department. Hospital de Barcelona. Societat Cooperativa d'Instal·lacions Assistencials Sanitàries (SCIAS). Barcelona, Spain.

⁵Pharmacy Department. Hospital de Barcelona. Societat Cooperativa d'Instal·lacions Assistencials Sanitàries (SCIAS). Barcelona, Spain.

⁶Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva. Hospital Universitario Virgen Macarena / Departamento de Medicina, Universidad de Sevilla / Instituto de Biomedicina de Sevilla, Seville, Spain.

#Corresponding author

Yolanda Meije, MD, PhD.

Infectious Disease Unit - Internal Medicine Department

27 Hospital de Barcelona. SCIAS

28 Diagonal 660, 08034, Barcelona

29 Phone: + 34 932 54 24 00

30 E-mail: yolandameije@gmail.com

31

32 **Running Title**

33 Carbapenem-sparing antibiotics for ESBL/Amp-C

34

35 **Abbreviations**

36 ESBL: Extended-spectrum β -lactamase

37 Amp-C: Amp-C β -lactamase

38 BL/BLIs: β -lactam/ β -lactamase inhibitor combinations

39 IV: Intravenous

40 TMP-SMX: Trimethoprim-Sulfamethoxazole

41

42 **Key words**

43 Carbapenem-sparing antibiotics, Enterobacteriaceae bacteremia, stewardship, extended-
44 spectrum β -lactamase, Amp-C β -lactamase, cotrimoxazole, trimethoprim-
45 sulfamethoxazole, quinolones, ciprofloxacin.

46

47 Some of the data contained in this article were presented at the 55th Interscience
48 Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and at the 28th
49 International Congress of Chemotherapy Meeting (ICC), San Diego, USA, 2015.

50 ABSTRACT

51 Introduction: Carbapenems are considered the treatment of choice for extended-spectrum
52 β -lactamase (ESBL) or Amp-C β -lactamase-producing Enterobacteriaceae bacteremia.
53 Data on the effectiveness of non-intravenous carbapenem-sparing antibiotic options are
54 limited.

55 Objective: To compare the 30 day-mortality and clinical failures associated with the use of
56 carbapenems vs an alternative non-intravenous antibiotic for the definitive treatment of
57 ESBL/Amp-C positive Enterobacteriaceae bacteremia.

58 Methods: This is a 12-year retrospective study (2004 - 2015) including all patients with
59 bacteremia due to ESBL/Amp-C-producing Enterobacteriaceae. Given the lack of
60 randomization of the initial therapies, a propensity score for receiving carbapenems was
61 calculated.

62 Results: There were 1115 patients with a first episode of bacteremia due to *E. coli* or *K.*
63 *pneumoniae*, of which 123 were ESBL/Amp C-positive (11%). There were 101 eligible
64 patients: 59 in the carbapenem group and 42 in the alternative treatment group
65 (cotrimoxazole 59.5%, quinolones 21.4%). The most frequent sources of infection were
66 urinary (63%) and biliary (15%). Compared to the carbapenem group, patients treated with
67 the alternative regimen had a shorter hospital stay (median [IQR]: 7 days [5-10] vs 12 days
68 [9-18], $p<0.001$). The use of an alternative non-IV treatment did not increase mortality (OR
69 0.27; 95% CI 0.05-1.61; $p=.15$). After controlling for confounding factors with the
70 propensity score, the adjusted OR of carbapenem treatment was 4.95; 95% CI (0.94-
71 26.01, $p=.059$).

72 Conclusion: Alternative non-IV carbapenem-sparing antibiotics could have a role in the
73 definitive treatment of ESBL/Amp-C-positive Enterobacteriaceae bloodstream infections,
74 allowing a reduction in carbapenem use. The use of cotrimoxazole in this setting has
75 shown favourable results.

76

77 INTRODUCTION

78 Extended-spectrum β -lactamase (ESBL) or Amp-C β -lactamase (Amp-C)-producing
79 Enterobacteriaceae have been increasingly implicated in health care- and community-
80 associated bacteremia (1). Effective treatment of ESBL or Amp-C bacteremia has become
81 a major challenge due to frequent resistance to various antibiotics and the existence of
82 mechanisms of co-resistance in this setting (2). At present, carbapenems are the treatment
83 of choice for ESBL bacteremia (3). However, increasing carbapenem resistance among
84 Enterobacteriaceae, as well as in other bacteria, calls for a more judicious approach to
85 carbapenem use (4).

86
87 Previous studies of empiric treatment of ESBL Enterobacteriaceae bacteremia with beta-
88 lactam/beta-lactam inhibitor combinations (BL/BLIs) are contradictory (3, 5–7). These
89 discrepant results may be due to differences in the source of infection, the genetic
90 background of the microorganism, or local epidemiology (8). Nevertheless, evidence is
91 emerging that empiric or definitive treatment with BL/BLIs is probably as effective as
92 carbapenem therapy in the setting of ESBL (*E. coli* or *K. pneumoniae*) bacteremia (9–11).
93 Data regarding the usefulness of carbapenem-sparing antibiotics other than BL/BLIs for
94 definitive treatment have also been reported, though also within an IV regimen (12–14).
95 The effectiveness of non-intravenous (oral or intramuscular) antibiotic treatment for the
96 management of ESBL or Amp-C bacteremia has not been widely assessed to date (3, 15).
97 At our cooperative non-profit private hospital, patients with ESBL or Amp-C
98 Enterobacteriaceae bacteremia frequently undergo definitive treatment with an orally
99 administered antimicrobial agent. This hospital encourages close follow-up of patients who
100 may re-contact their doctor directly if fever or other signs of possible infection appear after
101 discharge.

102

103 The aim of this study was to compare the 30-day mortality and clinical failure in two
104 groups: patients receiving carbapenems vs an alternative therapy, based on a non-IV
105 carbapenem-sparing antibiotic regimen, for the definitive treatment of ESBL or Amp-C-
106 positive Enterobacteriaceae bacteremia.

107

METHODS

Study design, setting and participants

This 12-year retrospective study (January 2004 - December 2015) was conducted at a tertiary general hospital, with 250 beds in Barcelona, Spain. Patients over age 15 with community-acquired or healthcare-associated bacteremia due to ESBL or Amp-C-producing Enterobacteriaceae were included. Patients who died in the first 72h or those without one-month follow-up were excluded. If patients experienced more than one bacteremic episode, only the first episode was included. We recorded the prescribed antibiotic in each case, as selected by the patient's attending physician. All episodes were identified from the electronic microbiological database. The patients' clinical information was collected from electronic clinical charts and electronic pharmacological database. The follow up was performed by either the electronic clinical charts or by telephone if the patient had been discharged. This study was approved by the institutional review board for clinical trials.

End-points

The primary outcome measure was the 30-day mortality rate, and the secondary outcomes were clinical failure within 30 days of onset of bacteremia and length of hospital stay.

Variables and Definitions

Bacteremia was defined as the isolation of organisms in one or more separately obtained blood culture with compatible clinical features. The cases of bacteremia were categorized as nosocomial, healthcare-associated, or community-acquired in accordance with the criteria of Friedman et al¹⁶. Infections were defined as urinary tract, biliary, incisional wound, soft-tissue, catheter-related or primary bloodstream infection, in accordance with the Centres for Disease Control and Prevention guidelines (16). The following patients

were considered immunocompromised: those receiving corticosteroids at a dose of ≥ 20 mg prednisone or equivalent for ≥ 2 weeks, those with neutropenia (absolute neutrophil count below 500/mm³) or those receiving anticancer chemotherapy in the previous six months. Chronic kidney disease (CKD) was defined and staged according to the Kidney Disease Improving Global Outcomes definition and classification (17). Charlson comorbidity score was defined as previously described by Charlson et al (18). The severity of bacteremia on the day of onset was graded with the Pitt bacteremia score (19). Source control was defined as any kind of intervention apart from antibiotic treatment applied to solve the infection, such as surgical treatment, abscess drainage or catheter withdrawal. Sepsis or septic shock was defined according to current definitions (20).

Antimicrobial therapy was regarded as empirical if administered before the susceptibility test results were available. Modification of treatment was defined as a change to an active antibiotic after the culture result became available, in accordance with the pathogen's *in vitro* susceptibility pattern. Definitive therapy was defined as an active antibiotic administered for > 50% of the total duration of antimicrobial therapy after the antibiogram result. Treatment was defined as appropriate when an active antimicrobial agent, determined by *in vitro* susceptibility testing, was administered at the usual recommended dose. Clinical failure was defined as persistence of bacteremia (i.e. positive blood cultures for the same Enterobacteriaceae after 72 hours of active antibiotic treatment by *in vitro* susceptibility), persistence of fever or sepsis, death, or relapse during a 30-day follow-up, defined as positive blood cultures for the same microorganism (after a previous negative result). Length of stay was defined as the time from the first positive blood culture to discharge.

Microbiological analysis

Microbiological identification and antibiotic susceptibility tests were carried out using the MicroScan WalkAway system (Beckman Coulter, Inc., Brea, CA). Presence of ESBL and/or AMPc was screened in all isolates with diminished susceptibility to cephalosporins by Microscan System, and confirmed by double disc synergy test (DDST), combination disc test, gradient test method, or molecular characterization by PCR, according to CLSI (Clinical & Laboratory Standards Institute) and EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines. The β -lactams used for confirmation, testing their synergistic effect with amoxicillin-clavulanate were: ceftazidime, cefotaxime, and aztreonam. The following β -lactams were used for confirmation, testing their synergistic effect with amoxicillin-clavulanate: ceftazidime, cefotaxim and aztreonam.

During 2004-2006 period, in vitro susceptibility tests were interpreted based on the CLSI breakpoints (Clinical and Laboratory Standards Institute: M100: Performance Standards for Antimicrobial Susceptibility Testing) (21), and during 2007-2015 on the EUCAST breakpoints (European Committee on Antimicrobial Susceptibility Testing) (22).

During the study period, the microbiology department at our hospital did not have access to PCR for the study of Amp C beta-lactamase-producing *Escherichia coli*. As we were unable to establish whether *E.coli*-AmpC enzymes were encoded by chromosomal or plasmid genes, we excluded all AmpC-*E. coli* to prevent potential confounding.

Statistical analysis

Quantitative variables were expressed as medians and interquartile ranges (IQR); categorical variables were reported as absolute numbers and percentages. To detect significant differences between groups, we used the Chi-square test or Fisher exact test for categorical variables, and the Student t test or Mann-Whitney U test for continuous

185 variables, as appropriate. Independent predictors for 30-day mortality were identified by
186 logistic regression analysis.

187

188 Given the lack of randomization of the initial therapies, a propensity score for receiving
189 carbapenems was estimated using a backward stepwise logistic regression model that
190 included variables with P values $\leq .25$ in the univariate analysis, plus other variables
191 considered relevant in deciding the empiric treatment. The following variables were
192 included: age, sex, Pitt index, active cancer, chronic kidney disease, source of
193 bloodstream infection, empiric treatment (as appropriate or not) and the time without
194 effective treatment. An Inverse probability of treatment weighting (IPTW) logistic
195 regression using the propensity score was fitted to estimate the risk of mortality due to
196 carbapenem administration. The weights to the propensity score were finally obtained after
197 fitting a logistic regression model for use of carbapenem as outcome. The model obtained
198 had an Area under ROC curve of 0.77.

199 The statistical analysis was conducted using SPSS software for Windows, version 17.0
200 (SPSS Inc., Chicago, IL, USA) and STATA 13.1 (Statacorp College Station, Tx, USA)

201

202 RESULTS

203 During the study period, there were 1309 patients with a first episode of bacteremia due to
 204 Enterobacteriaceae (1115 due to *E. coli* or *K. pneumoniae*) of which 123 (11%) were
 205 ESBL or Amp C-positive *E. coli* or *K. pneumoniae*. Twenty two patients were excluded
 206 (Figure 1), resulting in a final cohort of one hundred and one patients, which were grouped
 207 as per type of treatment: 59 in the carbapenem group and 42 in the alternative non-IV
 208 treatment group (TMP-SMX 25, quinolones 9, aminoglycosides 5, fosfomycin 2,
 209 amoxicillin/clavulanate 1).

210
 211 The in vitro susceptibility rate for various antibiotics for ESBL/Amp-C-producer strains was
 212 as follows: carbapenem 100%, aminoglycosides 76%, piperacillin/tazobactam 59%, TMP-
 213 SMX 38%, amoxicillin/clavulanate 27% and quinolones 14%.

214
 215 The most frequent infection sources were urinary (63%), biliary (15%) and unknown
 216 source (8%), followed by catheter-related (6%), intra-abdominal (5%), surgical wound/soft
 217 tissues (2%) and prosthetic joint infection (1%). The clinical and demographic
 218 characteristics of each group are shown in Table 1. There were no differences between
 219 groups (carbapenems vs alternative therapy) in terms of age, comorbidity, infection
 220 source, severity of underlying disease, time of empiric or definitive treatment. Compared to
 221 the carbapenem group, the patients treated with the alternative regimen had lower median
 222 Pitt score.

223
 224 Source control was performed in five patients out of 42 (12%), in the alternative group:
 225 three underwent catheter removal due to a catheter-related bacteremia and two underwent
 226 endoscopic retrograde cholangiopancreatography due to a bacteremia of biliary source.
 227 Source control was performed in ten patients out of 59 (17%), in the carbapenem group:

three underwent endoscopic retrograde cholangiopancreatography, five required double J catheter or percutaneous nephrostomy, one required debridement and implant retention, and one needed an abdominal surgery.

During the 30-days of follow up, among the 59 carbapenem treated patients, 6 (10%) died and 9 (15%) were considered as clinical failure (including the 6 patients who died), of which 3 were due to bacteremia relapse. In the non-carbapenem group, two patients (5%) died, which were also considered as clinical failure, and one of them had also previously developed bacteremia relapse (Table1). The two patients who died in the alternative group had a disseminated cancer (bladder and colon cancer). Among the 6 patients who died in the carbapenem group one had a pancreas tumor and the rest of them were patients with multiple comorbidities.

Compared to the carbapenem group, the patients treated with the alternative regimen had a shorter hospital stay (median [IQR]: 7 days [5-10] vs. 12 days [9-18], $p < 0.001$), (table 1).

In the alternative treatment group, two patients receiving TMP-SMX died due to an ESBL *E. coli* bacteremia (2/25 - 8%), both of which had advanced neoplastic disease (as previously described). This percentage is not higher than the 30 day mortality observed in the carbapenem group (table 1).

Alternative group

TMP-SMX was the most frequent therapeutic agent selected in these patients. The clinical characteristics and source of bacteremia of patients who received alternative therapy as definitive treatment are shown in table 2, and the complete therapy regimen and length of therapy in the alternative group in table 3. When patients were switched to non-IV

254 antibiotics, they had received a median of 2.5 days (IQR 0-6 days) of intravenous
255 appropriate therapy.

256

257 **Multivariate and propensity score analysis**

258 In the univariate analysis, nosocomial acquisition (OR 4.08; 95% CI 1.10-15.11; p=.035),
259 chronic kidney disease (OR 6.22; 95% CI 1.53-25.27; p=.01) and the microorganism (*K.*
260 *pneumoniae* compared with *E. coli*) (OR 3.85; 95% CI 1.05-14.20; p=.04), were
261 independent predictors of clinical failure. The use of an alternative non-IV treatment was
262 not related to mortality (OR 0.27; 95% CI 0.05-1.61; p=.15) (table 4). After controlling for
263 confounding with the propensity score, the adjusted OR of carbapenem treatment was
264 4.95; 95% CI (0.94-26.01, p=.059), (table 5).

265

DISCUSSION

In this study we have observed that the use of alternative non-IV carbapenem-sparing antibiotics for definitive treatment of ESBL or Amp-C-positive Enterobacteriaceae bloodstream infections was not related to greater mortality. In fact we did not find differences in either the primary outcome, 30-day mortality (6 [10%] vs. 2 [5%], $p=0.46$) nor the secondary outcome, clinical failure (9 [15%] vs. 2 [5 %], $p=0.12$) for carbapenem group vs. non-IV carbapenem-sparing antibiotics. Moreover, the use of alternative treatment was associated with a shorter hospital stay.

Some reports have evaluated the efficacy of IV carbapenem-sparing antibiotics in this setting, including cephamycins, BL/BLIs or fluoroquinolones, and have presented both positive (5, 9, 12, 13, 23) and negative outcomes (24, 25). In a metanalysis (3), the use of empirical quinolones (oral or intravenous) for ESBL Enterobacteriaceae bacteremia was associated with a higher mortality than carbapenems, but mortality was similar when quinolones were used as definitive therapy. However, even in the carbapenem-sparing setting, some studies have shown prior exposure to fluoroquinolones or β -lactam to be independent risk factors for ESBL or carbapenem-resistant enterobacteriae infections (26, 27). Therefore, these antibiotics would probably not be the best options for the treatment of these infections.

To our knowledge, there is no published experience with other oral alternatives such as TMP-SMX or fosfomycin for the treatment of ESBL Enterobacteriaceae bacteremia (28). Published experience with TMP-SMX for the treatment of ESBL or Amp-C infections in patients without bacteremia is also scarce. Park *et al.* showed that non-carbapenem antibiotics (which include 5 patients treated with TMP-SMX) had a similar efficacy to carbapenems among a case series of pyelonephritis, however the outcome of patients

treated with TMP-SMX was not specified (29). TMP-SMX was the most frequent option chosen as non-IV, carbapenem-sparing, definitive treatment in our study (mainly for urinary and biliary sources); no complications were found related to this use. Our experience with TMP-SMX, after confirming antibiotic susceptibility (38% of the strains of ESBL infections in our setting), is promising. This option may prevent the emergence of resistance, it allows for the administration of an oral regimen, and it could shorten the hospital stay.

Studies of the efficacy of non-IV carbapenem-sparing agents for infections caused by ESBL/Amp-C-producing Enterobacteriaceae have focused mainly on urinary tract infections (30, 31), have not assessed cases of bacteremia, and have addressed mainly patients with ESBL-*E.coli* infections. Since most of the available drugs (TMP-SMX, quinolones, fosfomycin) have high urinary levels, further studies should determine if this alternative non-IV carbapenem-sparing agents are also useful for the treatment of other bacteremic foci (abdominal) and for ESBL-*Klebsiella* infections.

Data on non-IV carbapenem-sparing treatments could help reduce carbapenem use, which is crucial in order to contain the spread of carbapenem resistance (32), to reduce its impact on global hospital ecology (33), and to shorten hospital stays. As demonstrated, hospital stays in the alternative treatment group were significantly shorter in our study population without a negative impact in terms of relapse or early re-admission. The benefits associated with non-prolonged hospitalization in terms of cost-effectiveness and comorbidity have been already demonstrated (34).

This study has certain limitations. The retrospective design could not exclude the possibility that patients with more severe infections were preferably treated with

carbapenems without subsequent treatment with a non-carbapenem. All cases were included in this retrospective study. Further, the sample size may be too small to achieve adequate statistical power and selection by indication may bias the results. However we tried to balance this limitation by adjusting our results using a propensity score analysis, and did not observe changes in estimation effects. This study may not account for all the variables that may have influenced the decision to use carbapenems and thus might influence the OR; similarly, the goodness of model fit for calculating propensity score weights might be underpowered (AUC=.77). We also could not characterize the ESBL genes or investigate the MIC distribution for all study isolates. Finally, the study included mostly bloodstream infections due to *E. coli* which means that these results cannot be extrapolated to *K. pneumoniae* and mixed ESBL/amp-C-positive Enterobacteriaceae or other species of the Enterobacteriaceae family.

In spite of these limitations, the possibility that non-IV antibiotics could be used for the definitive treatment of (ESBL)-Amp-C-positive Enterobacteriaceae bloodstream infections is promising. Our data supports the use of TMP-SMX as a carbapenem-sparing alternative therapy which could reduce carbapenem use and shorten hospital stays. Larger prospective interventional studies are now required to definitively assess the efficacy of oral carbapenem-sparing antibiotics for the treatment of ESBL-Amp-C-positive Enterobacteriaceae bacteremia.

ACKNOWLEDGMENTS

We thank Jay A Fishman for his critical review, Santi Pérez Hoyos and Alex Sànchez for statistical study and Michael Maudsley for English language support and editorial assistance. CP, NF-H and JR-B are supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001 and 0003), which is co-financed by European Development Regional Fund “A way to achieve Europe” , Operative Programme Intelligent Growth 2014 - 2020.

TRANSPATENCY DECLARATION

The authors have no conflicts of interest to declare.

REFERENCES

1. Arnaud I, Maugat S, Jarlier V, Astagneau P, National Early Warning, Investigation and Surveillance of Healthcare-Associated Infections Network (RAISIN)/multidrug resistance study group. 2015. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013. *Euro Surveill* 20:30014.
2. Pitout JD, Laupland KB. 2008. Extended-spectrum β -lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis* 8:159–166.
3. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. 2012. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β -lactamases: a systematic review and meta-analysis. *J Antimicrob Chemother* 67:2793–2803.
4. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. 2015. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. *Euro Surveill* 20:30062.
5. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended-Spectrum Beta-Lactamases—Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. β -Lactam/ β -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli*: a post hoc analysis of prospective cohorts. *Clin Infect Dis* 54:167–74.
6. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group. 2015. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients

with extended-spectrum β -lactamase bacteremia. Clin Infect Dis 60:1319–25.

7. Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D. 2015. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Infect Control Hosp Epidemiol 36:981–5.

8. Perez F, Bonomo RA. 2015. Bloodstream Infection Caused by Extended-Spectrum β -Lactamase-Producing Gram-Negative Bacteria: How to Define the Best Treatment Regimen? Clin Infect Dis 60:1326–9.

9. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh P-R, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J. 2016. A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother 60:4159–69.

10. Ng TM, Khong WX, Harris PNA, De PP, Chow A, Tambyah PA, Lye DC. 2016. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. PLoS One 11:e0153696.

11. Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M,

- 404 Rodríguez-Baño J, Ruiz-Camps I, Sukiennik TC, Tebe C, Carratalà J, BICAR Study
405 Group. 2017. Efficacy of β -Lactam/ β -Lactamase Inhibitor Combinations for the
406 Treatment of Bloodstream Infection Due to Extended-Spectrum- β -Lactamase-
407 Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
408 Antimicrob Agents Chemother 61:e00164-17.
- 409 12. Matsumura Y, Yamamoto Enterobacteriaceae M, Nagao M, Komori T, Fujita N,
410 Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S.
411 2015. Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment
412 of Extended-Spectrum- β -Lactamase-Producing *Escherichia coli* Bacteremia.
413 Antimicrob Agents Chemother 59:5107–5113.
- 414 13. Lo C-L, Lee C-C, Li C-W, Li M-C, Hsueh P-R, Lee N-Y, Ko W-C. 2017.
415 Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum
416 beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. J Microbiol
417 Immunol Infect 50:355–361.
- 418 14. Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A,
419 Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-
420 Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M,
421 Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J,
422 Lowman W, Hsueh P-R, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA,
423 Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J, Spanish Network for
424 Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream
425 Infections and Sepsis (ESGBIS)/INCREMENT Group. 2017. Empiric Therapy With
426 Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-
427 Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the
428 INCREMENT Cohort. Clin Infect Dis 65:1615–1623.
- 429 15. Rodríguez-Baño J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San

- 430 Francisco C, Gudiol C, Horcajada JP, López-Cerero L, Martínez JA, Molina J,
431 Montero M, Paño-Pardo JR, Pascual A, Peña C, Pintado V, Retamar P, Tomás M,
432 Borges-Sa M, Garnacho-Montero J, Bou G, Study Group of Nosocomial Infections
433 (GEIH) of the Spanish Society of Infectious Diseases, Infectious Diseases (SEIMC).
434 2015. Executive summary of the diagnosis and antimicrobial treatment of invasive
435 infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish
436 Society of Infectious Diseases and Clinical Microbiology (SEIMC). *Enferm Infecc*
437 *Microbiol Clin* 33:338–41.
- 438 16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. 1988. CDC definitions for
439 nosocomial infections, 1988. *Am J Infect Control* 16:128–40.
- 440 17. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw DDE,
441 Hostetter TH, Lameire N, Eknoyan G. 2005. Definition and classification of chronic
442 kidney disease: A position statement from Kidney Disease: Improving Global
443 Outcomes (KDIGO). *Kidney Int* 67:2089–2100.
- 444 18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of
445 classifying prognostic comorbidity in longitudinal studies: development and
446 validation. *J Chronic Dis* 40:373–83.
- 447 19. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. 1989. Antibiotic therapy
448 for *Pseudomonas aeruginosa* bacteremia: outcome correlations in a prospective
449 study of 200 patients. *Am J Med* 87:540–6.
- 450 20. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M,
451 Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, Hotchkiss RS, Levy MM,
452 Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent J-L, Angus
453 DC. 2016. The Third International Consensus Definitions for Sepsis and Septic
454 Shock (Sepsis-3). *JAMA* 315:801–10.
- 455 21. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth

- 456 Informational Supplement. M100-S16 Vol 26 n°3. January 2006. Clinical and
457 Laboratory Standards Institute.
- 458 22. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables
459 for interpretation of MICs and zone diameters. Version 5.0, 2015.
460 <http://www.eucast.org>.
- 461 23. Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G. 2016. Cefmetazole for
462 bacteremia caused by ESBL-producing Enterobacteriaceae comparing with
463 carbapenems. BMC Infect Dis 16:427.
- 464 24. Lee C-H, Su L-H, Chen F-J, Tang Y-F, Chien C-C, Liu J-W. 2015. Clinical and
465 microbiologic characteristics of adult patients with recurrent bacteraemia caused by
466 extended-spectrum β -lactamase-producing *Escherichia coli* or *Klebsiella*
467 *pneumoniae*. Clin Microbiol Infect 21:1105.e1-8.
- 468 25. Wu U-I, Chen W-C, Yang C-S, Wang J-L, Hu F-C, Chang S-C, Chen Y-C. 2012.
469 Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-
470 lactamase-producing *Escherichia coli*: a propensity score analysis. Int J Infect Dis
471 16:e47-52.
- 472 26. Falagas ME, Rafailidis PI, Kofteridis D, Vartzili S, Chelvatzoglu FC, Papaioannou V,
473 Maraki S, Samonis G, Michalopoulos A. 2007. Risk factors of carbapenem-resistant
474 *Klebsiella pneumoniae* infections: a matched case control study. J Antimicrob
475 Chemother 60:1124–1130.
- 476 27. Chopra T, Marchaim D, Johnson PC, Chalana IK, Tamam Z, Mohammed M, Alkatib
477 S, Tansek R, Chaudhry K, Zhao JJ, Pogue JM, Kaye KS. 2015. Risk factors for
478 bloodstream infection caused by extended-spectrum β -lactamase-producing
479 *Escherichia coli* and *Klebsiella pneumoniae*: A focus on antimicrobials including
480 cefepime. Am J Infect Control 43:719–23.
- 481 28. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. 2018. Treatment of

- 482 Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and
- 483 Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev 31:e00079-17.
- 484 29. Park SH, Choi S-M, Chang YK, Lee D-G, Cho S-Y, Lee H-J, Choi J-H, Yoo J-H.
- 485 2014. The efficacy of non-carbapenem antibiotics for the treatment of community-
- 486 onset acute pyelonephritis due to extended-spectrum β -lactamase-producing
- 487 *Escherichia coli*. J Antimicrob Chemother 69:2848–56.
- 488 30. Ipekci T, Seyman D, Berk H, Celik O. 2014. Clinical and bacteriological efficacy of
- 489 amikacin in the treatment of lower urinary tract infection caused by extended-
- 490 spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. J
- 491 Infect Chemother 20:762–7.
- 492 31. de La Blanchardière A, Dargère S, Guérin F, Daurel C, Saint-Lorant G, Verdon R,
- 493 Cattoir V. 2015. Non-carbapenem therapy of urinary tract infections caused by
- 494 extended-spectrum β -lactamase-producing Enterobacteriaceae. Med Mal Infect
- 495 45:169–72.
- 496 32. Lim CL-L, Lee W, Lee AL-C, Liew LT-T, Nah SC, Wan CN, Chlebicki MP, Kwa AL-H.
- 497 2013. Evaluation of Ertapenem use with impact assessment on extended-spectrum
- 498 beta-lactamases (ESBL) production and gram-negative resistance in Singapore
- 499 General Hospital (SGH). BMC Infect Dis 13:523.
- 500 33. Pletz MWR, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, Kurowski M, Nord
- 501 CE, Lode H. 2004. Ertapenem pharmacokinetics and impact on intestinal microflora,
- 502 in comparison to those of ceftriaxone, after multiple dosing in male and female
- 503 volunteers. Antimicrob Agents Chemother 48:3765–72.
- 504 34. Conley J, O'Brien CW, Leff BA, Bolen S, Zulman D. 2016. Alternative Strategies to
- 505 Inpatient Hospitalization for Acute Medical Conditions: A Systematic Review. JAMA
- 506 Intern Med 176:1693–1702.

Table 1. Characteristics of patients with bloodstream infections caused by extended-spectrum b-lactamase-producing Enterobacteriaceae according to definitive therapy.

	Definitive treatment		<i>p</i>
	Carbapenem N=59 pt	Alternative treatment N=42 pt	
Age, years, median, (IQR)	79 (70-86)	72 (66-84)	.27
Male sex	34 (58%)	28 (67%)	.36
Diabetes Mellitus	11 (19%)	7 (17%)	.80
Chronic kidney disease	24 (41%)	11 (26%)	.13
Immunosuppression	6 (10%)	5 (12%)	1.00
Cancer	11 (19%)	13 (31%)	.15
Charlson index, median, (IQR)	4 (3-6)	4 (2-7)	.69
Sepsis / septic shock	15 (25%)	7 (17%)	.29
Pitt score, median (IQR)	0 (0-2)	0 (0-1)	.004
Nosocomial acquisition	19 (32%)	15 (36%)	.71
Health-care associated	21 (36%)	11 (26%)	.32
ESBL/ ampC Microorganism			.89
<i>E. coli</i>	47 (80%)	33 (79%)	
<i>K. pneumoniae</i>	12 (20%)	9 (21%)	
Bloodstream infection source			.12

Urinary tract	34 (58%)	30 (71%)	
Biliary tract	12 (20%)	3 (7%)	
Catheter related	2 (3%)	4 (10.3%)	
Source control ^a	10 (17%)	5 (12%)	.48
Appropriate empirical therapy	32 (54%)	13 (31%)	.074
Partially appropriate ^b	3 (5%)	4 (9%)	
Delay of appropriate therapy, days, median (IQR) ^c	0 (0-3)	2 (0-3)	.006
Empirical treatment duration, days, median (IQR)	2 (2-4)	3 (2-3)	.79
Definitive treatment duration, days, median (IQR)	12 (7-14)	12 (10-14)	.23
OUTCOMES			
Hospital stay after BSI, median (IQR)			
Overall	12 (9-18)	7 (5-10)	< 0.0001
Survivors	12 (8.5-18)	7(4,25-10)	< 0.0001
Cure failure ^d	9 (15%)	2 (5%)	.12
Relapse (30 days follow-up)	3 (5%)	1 (2%)	.64
Mortality (30 days follow-up)	6 (10%)	2 (5%)	.46

^a Source control: any kind of intervention apart from antibiotic treatment to resolve the BSI (bloodstream infection) : e.g., surgical treatment, abscess drainage or catheter withdrawal. ^b Partially: the antibiotic was appropriate for part of the duration of the empiric treatment (e.g. the

patient received some days of appropriate treatment and some days of a non-appropriate antibiotic during the empiric therapy). ^c Delay of appropriate therapy: days without active treatment in terms of antibiotic susceptibility. ^d Cure failure includes bacteraemia persistence or recurrence/relapse.

Table 2. Clinical characteristics of patients with bloodstream infections caused by extended-spectrum b-lactamase-producing Enterobacteriaceae who received an alternative therapy as definitive treatment (carbapenem-sparing).

Patient	Definitive treatment	Sepsis / septic shock	Microorganism	BSI Source	Death	Cure	Relapse
1	TMP-SMX ^a PO ^b / 1 DS ^c tid ^d	No	<i>E. coli</i>	Urinary	No	Yes	No
2	TMP-SMX PO/ 1 DS bid ^e	No	<i>E. coli</i>	Urinary	No	Yes	No
3	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
4	TMP-SMX PO/ 1 DS bid	Septic shock	<i>K. pneumoniae amp C</i>	Catheter	No	Yes	No
5	TMP-SMX PO/ 1 DS bid	Sepsis	<i>K. pneumoniae amp C</i>	Urinary	No	Yes	No
6	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Biliary	No	Yes	No
7	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
8	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	Yes	No	No
9	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
10	TMP-SMX PO/ 1 DS bid	No	<i>K. pneumoniae amp C</i>	Biliary	No	Yes	No
11	TMP-SMX PO/ 1 DS bid	No	<i>K. pneumoniae amp C</i>	Urinary	No	Yes	No
12	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Primary ^f	No	Yes	No
13	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
14	TMP-SMX PO/ 1 DS bid	Sepsis	<i>E. coli</i>	Urinary	No	Yes	No
15	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Bowel	No	Yes	No
16	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Biliary	No	Yes	No
17	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
18	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
19	TMP-SMX PO/ 1 DS bid	Septic shock	<i>E. coli</i>	Urinary	No	Yes	No
20	TMP-SMX PO/ 1 DS bid	No	<i>K. pneumoniae</i>	Urinary	No	Yes	No
21	TMP-SMX PO/ 1 DS bid	Septic shock	<i>E. coli</i>	Urinary	No	Yes	No

22	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	Yes	No	Yes
23	TMP-SMX PO/ 1 DS bid	No	<i>K. pneumoniae</i>	Primary	No	Yes	No
24	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Primary	No	Yes	No
25	TMP-SMX PO/ 1 DS bid	No	<i>E. coli</i>	Urinary	No	Yes	No
26	Fosfomycin PO 500mg qid	No	<i>K. pneumoniae</i>	Urinary	No	Yes	No
27	Fosfomycin PO 500mg qid	No	<i>E. coli</i>	Urinary	No	Yes	No
28	Ciprofloxacin PO 500mg bid	No	<i>E. coli</i>	Urinary	No	Yes	No
29	Ciprofloxacin PO 500mg bid	Septic shock	<i>E. coli</i>	Urinary	No	Yes	No
30	Ciprofloxacin PO 500mg bid	No	<i>K. pneumoniae Amp C</i>	Catheter	No	Yes	No
31	Ciprofloxacin PO 500mg bid	No	<i>K. pneumoniae</i>	Catheter	No	Yes	No
32	Ciprofloxacin PO 500mg bid	No	<i>E. coli</i>	Urinary	No	Yes	No
33	Ciprofloxacin PO 750mg bid	No	<i>E. coli</i>	Catheter	No	Yes	No
34	Ciprofloxacin PO 500mg bid	No	<i>E. coli</i>	Urinary	No	Yes	No
35	Ciprofloxacin PO 500mg bid	No	<i>E. coli</i>	Abdominal	No	Yes	No
36	Ciprofloxacin PO 500mg bid	No	<i>E. coli</i>	Urinary	No	Yes	No
37	Amoxicillin/clavulanate ER ^g PO 1000/62.5 mg qid	No	<i>E. coli</i>	Urinary	No	Yes	No
38	Gentamicin IM ^h 240 mg qd	No	<i>E. coli</i>	Urinary	No	Yes	No
39	Gentamicin IM 240 mg qd	Sepsis	<i>E. coli</i>	Urinary	No	Yes	No
40	Gentamicin 240 mg qd	No	<i>E. coli</i>	Urinary	No	Yes	No
41	Amikacin IM 1 g qd	No	<i>E. coli</i>	Urinary	No	Yes	No
42	Gentamicin 240 mg qd	No	<i>E. coli</i>	Urinary	No	Yes	No

^aTMP-SMX: Trimethoprim-Sulfamethoxazole. ^bPO: Oral administration. ^cDS: double strength. ^dtid: three times a day. ^ebid: twice a day ^fPrimary: No source identified. ^gER: extended release. ^hIM: intramuscular administration. ⁱqd: once daily.

Table 3. Complete therapy regimen and duration of treatment of patients with bloodstream infections caused by extended-spectrum b-lactamase-producing Enterobacteriaceae who received an alternative therapy as definitive treatment (carbapenem-sparing).

Patient	Empiric Treatment (Appropriate)	Duration, days	Effective modification treatment (Same as definitive)	Duration, days	Definitive treatment	Duration , days
1	BL/BLIs ^a -Cephalosporin (No)	2	Carbapenem (No)	1	TMP-SMX ^b	28
2	Quinolones-AMG ^c (No)	5	TMP-SMX (Yes)	10		
3	Cephalosporin- Carbapenem (Partially) ^d	4	Carbapenem (No)	5	TMP-SMX	14
4	Carbapenem (Yes)	3	Carbapenem (No)	6	TMP-SMX	10
5	BL/BLIs (Yes)	3	BL/BLIs (No)	2	TMP-SMX	8
6	Carbapenem- BL/BLIs (Yes)	6	TMP-SMX (Yes)	8		
7	BL/BLIs (Yes)	3	TMP-SMX (Yes)	9		
8	BL/BLIs (No)	3	Carbapenem (No)	3	TMP-SMX	11
Death						
9	BL/BLIs	1	TMP-SMX	11		

	(No)		(Yes)			
10	BL/BLIs	4	TMP-SMX	13		
	(No)		(Yes)			
11	BL/BLIs	3	Carbapenem	1	TMP-SMX	27
	(No)		(No)			
12	Quinolones	3	TMP-SMX	14		
	(No)		(Yes)			
13	Cephalosporin	2	TMP-SMX	21		
	(No)		(Yes)			
14	Carbapenem	2	Carbapenem	4	TMP-SMX	14
	(Yes)		(No)			
15	BL/BLIs-Quinolones	1	Carbapenem	3	TMP-SMX	7
	(No)		(No)			
16	BL/BLIs	2	Carbapenem	6	TMP-SMX	11
	(No)		(No)			
17	Cephalosporin- Quinolones	2	TMP-SMX	14		
	(No)		(Yes)			
18	Cephalosporin	3	Carbapenem	1	TMP-SMX	13
	(No)		(No)			
19	Carbapenem- TMP-SMX	4	TMP-SMX	11		
	(Yes)		(Yes)			
20	BL/BLIs- Carbapenem	3	Carbapenem	2	TMP-SMX	9
	(Yes)		(No)			
21	Carbapenem	3	Carbapenem	8	TMP-SMX	14
	(Yes)		(No)			
22	BL/BLIs- Quinolones	2	TMP-SMX	12		
Death	(No)		(Yes)			
23	Cephalosporin	3	TMP-SMX	18		

	(No)		(Yes)			
24	Cephalosporin	5	TMP-SMX	19		
	(No)		(Yes)			
25	Quinolones	4	TMP-SMX	15		
	(No)		(Yes)			
26	BL/BLIs- Carbapenem	4	Fosfomycin	14		
	(Partially)		(Yes)			
27	Cephalosporin- AMG	2	Carbapenem	5	Fosfomycin	15
	(Partially)		(No)			
28	BL/BLIs	1	Quinolones	14		
	(No)		(Yes)			
29	Carbapenem	3	Carbapenem	7	Quinolones	10
	(Yes)		(No)			
30	BL/BLIs	2	Carbapenem	2	Quinolones	10
	(No)		(No)			
31	Aztreonam	2	Quinolones	14		
	(No)		(Yes)			
32	BL/BLIs	3	Quinolones	25		
	(Yes)		(Yes)			
33	Aztreonam	2	AMG	2	Quinolones	10
	(No)		(No)			
34	BL/BLIs	2	Quinolones	16		
	(No)		(Yes)			
35	BL/BLIs	2	Carbapenem	6	Quinolones	8
	(Yes)		(No)			
36	Cephalosporin	5	Quinolones	10		
	(No)		(Yes)			
37	BL/BLIs	2	Carbapenem	2	Amoxicillin- clavulanate	10
	(Yes)		(No)			

38	BL/BLIs-AMG (Partially)	2	AMG (Gentamicin) (Yes)	12		
39	Cephalosporin (No)	2	Carbapenem (No)	5	AMG (Gentamicin)	8
40	Cephalosporin (No)	3	AMG (Gentamycin)(Yes)	21		
41	Cephalosporin (No)	2	Carbapenem (No)	5	AMG (Amikacin)	8
42	Carbapenem (Yes)	1	Carbapenem (No)	5	AMG Gentamicin)	7

^aBL/BLIs: b-lactam/b-lactamase inhibitor combinations. ^bTMP-SMX: Trimethoprim-Sulfamethoxazole. ^cAMG: Aminoglycoside. ^dPartially: the antibiotic was appropriate for part of the empiric treatment.

Table 4. Univariate and multivariate analysis. Relation between variables and failure.

• UNIVARIATE ANALYSIS		OR	(95%CI)	p-value
Age		0.99	(0.94; 1.03)	0.57
Sex (male)		1.79	(0.44; 7.14)	0.42
Diabetes Mellitus		0.43	(0.05; 3.59)	0.43
Chronic kidney disease		6.22	(1.53; 25.27)	0.011
Immunosuppression		2.00	(0.37; 10.73)	0.42
Cancer		1.23	(0.30; 5.07)	0.77
Charlson Index		1.08	(0.86; 1.35)	0.49
Sepsis / Septic Shock		0.33	(0.04; 2.72)	0.30
Pitt score		0.84	(0.54; 1.29)	0.42
Nosocomial acquisition		4.08	(1.10; 15.11)	0.03
Health-care associated		1.94	(0.55; 6.92)	0.30
ESBL microorganism	<i>K. pneumoniae</i>	3.85	(1.05;14.20)	0.042
Bloodstream infection source ¹	Urinary tract	1		0.52
	Catheter related	1.000	(1.00; 1.00)	
	Biliary tract	2.42	(0.53; 11.04)	
	Other	1.38	(0.25; 7.59)	
Appropriate empirical therapy	Yes	0.70	(0.18; 2.66)	0.84
	Partially ^b	1.19	(0.12; 11.71)	
Delay of appropriate therapy ^a		1.07	(0.73; 1.57)	0.74
Empirical treatment duration in days		1.004	(0.58; 1.72)	0.99
Definitive treatment duration in days		0.98	(0.89; 1.09)	0.75
Alternative non-IV treatment		0.28	(0.06; 1.35)	0.11
Hospital stay after BSI ^b		1.01	(0.99; 1.04)	0.34
• MULTIVARIATE ANALYSIS		OR	(95%CI)	p-value
Chronic kidney disease		11.19	(1.84; 67.94)	0.009
ESBL microorganism (<i>K. pneumoniae</i>)		7.86	(1.16-53.41)	0.035
Alternative non-IV treatment		0.27	(0.05-1.61)	0.15

^a Delay of appropriate therapy: days without active treatment in terms of antibiotic susceptibility.

^b BSI: bloodstream infection

Table 5. Propensity score analysis.

VARIABLE		OR	(95% CI)	p-value
Carbapenem group as definitive	Alternative treatment	1		0.0587
	Carbapenem	4.95	(0.94;26.01)	

Figure 1. Flow chart

pt: patient